Vivos Therapeutics
VVOS
16 hedge funds and large institutions have $647K invested in Vivos Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
9.07% less ownership
Funds ownership: 19.33% → 10.25% (-9.1%)
11% less funds holding
Funds holding: 18 → 16 (-2)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
79% less capital invested
Capital invested by funds: $3.12M → $647K (-$2.47M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$278K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$89.6K |
| 3 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
+$3.91K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$478 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$66 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$623K |
| 2 |
BTI
Blue Trust Inc
Alpharetta,
Georgia
|
-$22.9K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$956 |
| 4 |
BlackRock
New York
|
-$522 |
| 5 |
Morgan Stanley
New York
|
-$400 |
VVOS Hedge Fund Activity: Q1 2024 in Review
16 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q1 2024, worth a combined $647K — down 79% from $3.12M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of VVOS and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Armistice Capital, adding an estimated $278K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $623K sold.
- 16 institutional investors held Vivos Therapeutics (VVOS) as of Q1 2024, down from 18 in Q4 2023.
- Funds reported $647K of Vivos Therapeutics stock for Q1 2024, down 79% quarter-over-quarter.
- 2 funds opened new Vivos Therapeutics positions in Q1 2024 and 3 closed out, a net change of -1 holder.
- The largest Vivos Therapeutics buyer in Q1 2024 was Armistice Capital, an estimated $278K added.
- The largest Vivos Therapeutics seller in Q1 2024 was Schonfeld Strategic Advisors, an estimated $623K sold.
Based on aggregated 13F filings for Q1 2024.